Article - Arava

Proved processing rheumatoid arthritis marketed since 1998, also demonstrated efficiency in psoriatic arthritis. Arava - a first spoken disease, modified anti-rheumatic medicine (DMARD) therapy approved on this instruction European Commission.

Strasbourg, France - Aventis today declared that European Commission approved the new instruction for Arava (leflunomide): processing adult patient with active psoriatic arthritis (PsA).

The Results of the clinical studies (the central analysis: TOPAS), demonstrate Arava only provides the solving advantage on processing PsA: ” product very efficient in moderate joint and skins and consequently vastly perfects the quality a patient to lifes.” explains Gilles Brisson, Head Europe Aventis, “Besides product is well tolerated, easy to use, because of its spoken administrative route, and economic profitable. These features, do Arava main choice of the processing for patient with PsA.”

The Arthritis Psoriatic is potentially inflammatory disease of the blocking on which affects up to 30% patient with psoriasis, condition of the skin came to light through 1-3% populations approximately. PsA - most likely under diagnose; consequently spreading the truth can be more high. PsA is BOUND by significant disability, reducing quality to lifes and raised mortality. Approved and efficient election of the processing for patient with PsA are limited. The Classical agents used to address joint often do little to perfect the damages of the skin conversely.

PsA And psoriasis significant disease, affecting as on bound health so and emotional aspects to patient life. Accordingly, improvement quality to lifes is a critical purpose for therapeutic agent used to address PsA. Arava Demonstrated the significant improvements in contrast with in function status and in bound quality of the skin to lifes. The Index Quality to Lifes Dermatological on patient Arava leads to improvement of the skin bound quality to lifes 24% in contrast with index for psoriatic patient in outline.

Arava is Specified for processing adult patient by means of active rheumatoid arthritis as “disease-modify antirheumatic medicine” (DMARD), weakenning disease, which in inflammation in lining joint. This has shown to reduce the signs and rheumatoid arthritis, perfect the physical function and to delay the structured damage such as, erosions and joint-cosmic to narrow as evidenced by X-rays. Arava Offers as only-daily spoken dosing and can be used both in early and the end stage disease. There was Uncared-for in the UNITED STATES in 1998 and available in over 70 countries, including EU, Asia and a part of the Latin America.

Arava First continued the sale in 1998 in United Staff and has with be done available in 72 countries. In 2002, the worldwide sellouts Arava made sense 31.9 billionth yens ($300 million), according to approving the companies.

Filed under Men Health |